180 Life Sciences (ATNF) Competitors $2.67 -0.14 (-4.98%) As of 09/2/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. ABVC, ELYM, MGX, ZIVO, ALGS, BTAI, ADVM, INKT, QNTM, and MNOVShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include ABVC BioPharma (ABVC), Eliem Therapeutics (ELYM), Metagenomi (MGX), ZIVO Bioscience (ZIVO), Aligos Therapeutics (ALGS), BioXcel Therapeutics (BTAI), Adverum Biotechnologies (ADVM), MiNK Therapeutics (INKT), Quantum Biopharma (QNTM), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Its Competitors ABVC BioPharma Eliem Therapeutics Metagenomi ZIVO Bioscience Aligos Therapeutics BioXcel Therapeutics Adverum Biotechnologies MiNK Therapeutics Quantum Biopharma MediciNova ABVC BioPharma (NASDAQ:ABVC) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Does the media favor ABVC or ATNF? In the previous week, ABVC BioPharma had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.87 beat ABVC BioPharma's score of 0.63 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment ABVC BioPharma Positive 180 Life Sciences Very Positive Which has more volatility & risk, ABVC or ATNF? ABVC BioPharma has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Do insiders and institutionals believe in ABVC or ATNF? 11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are owned by institutional investors. 17.1% of ABVC BioPharma shares are owned by insiders. Comparatively, 38.2% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ABVC or ATNF more profitable? 180 Life Sciences has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. ABVC BioPharma's return on equity of -46.76% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharma-963.46% -46.76% -23.02% 180 Life Sciences N/A -141.25%-80.77% Which has higher valuation & earnings, ABVC or ATNF? ABVC BioPharma has higher revenue and earnings than 180 Life Sciences. ABVC BioPharma is trading at a lower price-to-earnings ratio than 180 Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$510K125.09-$4.90M-$0.17-15.94180 Life SciencesN/AN/A-$6.17M-$15.07-0.18 SummaryABVC BioPharma beats 180 Life Sciences on 7 of the 12 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.12M$3.12B$5.77B$9.77BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-0.1821.1082.3726.60Price / SalesN/A408.88536.82175.38Price / CashN/A43.5325.7028.92Price / Book0.928.1310.646.56Net Income-$6.17M-$53.35M$3.28B$266.04M7 Day Performance-13.87%0.45%-0.08%-0.58%1 Month Performance-24.58%9.94%10.36%6.24%1 Year Performance50.85%11.73%49.00%22.21% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life Sciences0.8996 of 5 stars$2.67-5.0%N/A+55.2%$16.12MN/A-0.187Positive NewsGap DownABVCABVC BioPharma0.345 of 5 stars$2.83-8.1%N/A+304.3%$66.62M$510K-16.6530ELYMEliem TherapeuticsN/A$2.23-3.0%N/A-68.1%$66.35MN/A-4.219MGXMetagenomi2.5541 of 5 stars$1.74-7.0%$10.00+474.7%-38.7%$65.31M$52.29M-0.74236Positive NewsZIVOZIVO Bioscience0.065 of 5 stars$17.01flatN/A+29.6%$64.93M$15.85K-3.4910Gap DownALGSAligos Therapeutics4.4633 of 5 stars$10.55-4.6%$50.00+373.9%-16.2%$64.90M$3.94M-0.5390News CoveragePositive NewsBTAIBioXcel Therapeutics4.0908 of 5 stars$4.05-1.2%$39.75+881.5%-61.4%$64.84M$2.27M-0.3290Short Interest ↑ADVMAdverum Biotechnologies3.5994 of 5 stars$3.08+1.7%$19.75+541.2%-56.2%$64.63M$1M-0.39190INKTMiNK Therapeutics1.959 of 5 stars$14.24-3.9%$37.50+163.3%+71.1%$64.41MN/A-4.9430Short Interest ↑Gap UpQNTMQuantum BiopharmaN/A$16.85-2.3%N/AN/A$64.30MN/A-1.20N/APositive NewsGap UpMNOVMediciNova2.0026 of 5 stars$1.31-2.2%$7.00+434.4%-12.7%$64.25M$1M-5.2410News CoverageGap Up Related Companies and Tools Related Companies ABVC Competitors ELYM Competitors MGX Competitors ZIVO Competitors ALGS Competitors BTAI Competitors ADVM Competitors INKT Competitors QNTM Competitors MNOV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThe Orphaned Well Crisis Hidden Across AmericaAcross the U.S., millions of abandoned oil and gas wells are leaking methane into the air — a costly and dange...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATNF Stock Alerts